News
Kiniksa Pharmaceuticals International
KNSA · NASDAQ
$83.17+$3.69 (+4.64%)TodayMarket closed ·
Prev close $79.48
Latest news
- NewsAvi Kapoor
Crude Oil Down Over 5%; Boeing Shares Rise After Q2 Results
- News
Kiniksa Pharmaceuticals Q2 EPS $0.30 Beats $0.27 Estimate, Sales $243.600M Beat $225.457M Estimate
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
- News
Kiniksa Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Kiniksa Pharmaceuticals Q1 EPS $0.27 Beats $0.19 Estimate, Sales $214.300M Beat $206.091M Estimate
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
- News
Earnings Scheduled For April 28, 2026
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis
- News
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts
- News
Kiniksa Pharmaceuticals Q4 Earnings Assessment
- News
Kiniksa Pharmaceuticals Q4 EPS $0.17 Misses $0.38 Estimate, Sales $202.127M Beat $195.005M Estimate.
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
- News
Earnings Scheduled For February 24, 2026
- News
Insights Ahead: Kiniksa Pharmaceuticals's Quarterly Earnings
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Provides Corporate Update
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
- NewsAvi Kapoor
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
- Press releaseGlobe Newswire
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
- News
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook
- NewsAvi Kapoor
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- NewsAvi Kapoor
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.